スタッフ紹介

助教/副医局長荘 拓也

Takuya Sho

専門分野

消化器病学、肝臓病学、肝癌治療

助教/副医局長　荘 拓也

学歴

1995年03月
秋田県立大館鳳鳴高校卒業
2002年03月
宮崎医科大学卒業
2010年03月
北海道大学大学院医学研究科病態制御学専攻医学博士課程修了

職務経歴

2002年05月
北海道大学病院研修医
2003年04月
北見赤十字病院内科
2003年10月
釧路赤十字病院内科
2004年04月
函館中央病院消化器内科
2005年04月
市立札幌病院消化器内科
2006年04月
北海道大学病院第三内科医員
2010年04月
北海道大学病院第三内科助教
2011年04月
市立稚内病院内科（地域医療支援指導医）
2014年04月
北海道大学病院消化器内科助教

所属学会・資格

  • 日本内科学会　認定医
  • 日本消化器病学会　専門医
  • 日本肝臓学会　専門医
  • 日本消化器内視鏡学会

受賞歴

  • 2019年　日本肝臓学会研究奨励賞
  • 2022年　第27回日本肝がん分子標的治療研究会最優秀演題AWARD

論文

  1. Sho T, Suda G, Yamamoto Y, Furuya K, Baba M, Ogawa K, Kubo A, Tokuchi Y, Fu Q, Yang Z, Kimura M, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Suzuki K, Izumi T, Meguro T, Terashita K, Takagi T, Ito J, Kobayashi T, Miyagishima T, Sakamoto N.
    Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150.
    Cancers (Basel). 2022 Aug 15;14(16):3938.
  2. Sho T, Morikawa K, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Sakamoto N.
    Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.
    World J Gastrointest Oncol. 2021 Dec 15;13(12):2076-2087.
  3. Sho T, Suda G, Ogawa K, Kimura M, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Shigesawa T, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N.
    Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.
    Hepatol Res. 2021 Sep;51(9):979-989.
  4. Sho T, Suda G, Ogawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Ito J, Yamamoto Y, Kobayashi T, Meguro T, Saga A, Miyagishima T, Terasita K, Takagi T, Kamiyama T, Taketomi A, Sakamoto N.
    Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria.
    Hepatol Res. 2020 Aug;50(8):966-977.
  5. Sho T, Suda G, Ogawa K, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Meguro T, Saga A, Miyagishima T, Yokoo H, Kamiyama T, Taketomi A, Sakamoto N.
    Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting.
    JGH Open. 2019 Jun 10;4(1):54-60.
  6. Izumi T, Sho T, Morikawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Umemura M, Shimazaki T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Kudo Y, Nishida M, Ono K, Baba M, Furuya K, Sakamoto N.
    Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter.
    Hepatol Res. 2019 Oct;49(10):1207-1217.
  7. Sho T, Suda G, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Izumi T, Kawagishi N, Baba M, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
    Intern Med. 2019 Mar 15;58(6):797-802.
  8. Sho T, Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Uebayashi M, Terashita K, Kobayashi T, Tsunematsu I, Onodera M, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Kawagishi N, Ohara M, Ono Y, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group.
    Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
    Hepatol Res. 2018 Jun;48(7):529-538.
  9. Sho T, Nakanishi M, Morikawa K, Ohara M, Kawagishi N, Izumi T, Umemura M, Ito J, Nakai M, Suda G, Ogawa K, Chuma M, Meguro T, Nakamura M, Nagasaka A, Horimoto H, Yamamoto Y, Sakamoto N.
    A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.
    Drugs R D. 2017 Sep;17(3):381-388.
  10. Sho T, Tsukiyama T, Sato T, Kondo T, Cheng J, Saku T, Asaka M, Hatakeyama S.
    TRIM29 negatively regulates p53 via inhibition of Tip60.
    Biochim Biophys Acta. 2011 Jun;1813(6):1245-53.